Website
News25/Ratings3
News · 26 weeks31+60%
2025-10-262026-04-19
Mix1690d
- SEC Filings8(50%)
- Other5(31%)
- Earnings2(13%)
- Analyst1(6%)
Latest news
25 items- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer TechnologyPreclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle("LNP")-delivered therapies related to rapid liver clearancePre-treatment with Nanoprimer followed by administration of LNP-delivered recombinant DNA ("LNP-DNA") designed for anti-tumor immunotherapy showed increased systemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING related inflammation compared to LNP-DNA administered without the Nanoprimer Data presented at the 2026 Annual Meeting of the American Association for Cancer Research PARIS and CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-cli
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 20-F filed by Nanobiotix S.A.20-F - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial ResultsGlobal development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerClinical results reported across multiple tumor types including esophageal cancer, pancreatic cancer, melanoma, head and neck cancer, and lung cancer that supported the broad potential of JNJ-1900 (NBTXR3) across solid tumors treated with radiotherapy next to the completion of the transfer of sponsorship for NANORAY-312Strengthened financial position through the closing of a non-dilutive royalty financing with HealthCare Royalty for up to $71 million and an amendment to the gl
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung CancerData presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of first data from the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage 3 inoperable non-small cell lung cancer, at the 2026 European Lung Cancer Conference. POSTER #297P: Novel Intratumoral Radioen
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31st, 2026, after the close of the U.S. market. This release will be followed by a conference call and webcast on Wednesday, April 1st, 2026, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive office
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX Statement Regarding Recent Media SpeculationPARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today issued the following statement in response to recent media speculation concerning intentions for a potential public take-over. Nanobiotix states that, to the best of its knowledge, there is no such intention to acquire control of the Company, and no process or assessment is being conducted toward that end. Additionally, the Company has identified factual inaccuracies in this media report which are not consistent with the Company's
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX to Participate in Investor Conferences in MarchPARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ:NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March: TD Cowen's Health Care ConferenceDate: Wednesday, March 4, 2026Location: Boston, MATime of the fireside chat: 11:10am ET / 5:10pm CETPresenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix UBS Biotech Summit Miami Date: Monday, March
- ANALYSTTD Cowen initiated coverage on NanobiotixTD Cowen initiated coverage of Nanobiotix with a rating of Buy
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext ParisPARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become effective after the market closes on Friday, December 19, 2025. The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading liste
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical OutlookFinancial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty ("HCRx") of a non-dilutive royalty financing valued up to $71 millionProgress in the JNJ-1900 (NBTXR3) global development program announced including first data from a Phase 1 esophageal cancer study sponsored by The University of Texas MD Anderson Cancer Center ("MD Anderson")Completed the NANORAY-312 sponsorship transfer to Johnson & Johnson in the majority of regionsAdvanced the Curadigm Nanoprimer program with updated plans for internal pipeline development and external collaborationsClinical updates from ongoing or completed JNJ-1900 (NBTXR3) Phase 1 studies sponsored by Nano
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External CollaborationsFour new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial proprietary internal pipeline of Nanoprimer products in addition to external collaborationsNew in vivo pre-clinical data evaluating the Nanoprimer in combination with therapeutic vaccines were presented at the 2025 Partnership Opportunities in Drug Delivery conference (PODD) that will serve as the foundation for an initial internal proprietary pipeline of Nanoprimer productsMomentum building for external collaborations featuring Nanoprimer platform combinations with numerous material transfer agreements already in placeChemistry, Manufacturing, and Con